FDA Briefing Reveals No Major Deficiencies, Moderna Stock Surges 9.1% in Single Day
Claire Weston
The FDA released a briefing document on Moderna's mRNA flu vaccine mFlusiva, finding no major flaws; the stock surged 9.1% in a single session. This means → the market now reads the biggest regulatory overhang as largely cleared, with the upcoming VRBPAC vote set to confirm — or deny — the rally's staying power.
What did the FDA briefing actually say?
The FDA called mFlusiva's profile "balanced, with no major flaws" but flagged evidence gaps in older adults and immunocompromised populations.
This means → the regulator did not raise a red flag, but did not give a clean pass either — the document amounts to a qualified green light, not an unconditional one.
Analysts read this tone as a favorable signal ahead of the VRBPAC vote — the advisory committee that votes on a vaccine's benefit-risk profile before the FDA makes a formal approval decision.
What was the "refuse-to-file" scare in February?
In February the FDA issued a refuse-to-file letter, citing "inadequate comparative trial design" — in plain terms = the agency said the clinical trial's control-group setup was flawed and sent the application back.
Days later the FDA reversed itself and withdrew the letter — a rare about-face that rattled investor confidence in the regulatory outlook.
This reflects why a merely balanced briefing could trigger a 9.1% single-day jump: the market had already priced in the worst case, so the retreat of fear itself became the catalyst.
Beyond the flu vaccine — what else is Moderna building?
Moderna named Ester Banque as Chief Commercial Officer, tasked with preparing the commercial launch of up to three new products planned for 2027–2028.
The pipeline includes a combined flu/COVID vaccine and a norovirus vaccine, both built on the mRNA platform — a technology that uses messenger RNA to teach human cells to produce an immune response on their own.
This means → Moderna is pivoting from a "COVID one-product company" to an mRNA platform company; whether the commercial roadmap holds will directly shape the stock's valuation thesis.
Why does the five-year cancer-vaccine data matter here?
Twelve days ago, Moderna and Merck released five-year long-term data for their personalized mRNA cancer vaccine — high-risk melanoma patients who received the vaccine plus Keytruda saw a 49% reduction in cancer recurrence or death and a 59% reduction in distant metastasis, compared with Keytruda alone.
Put simply = for the skin-cancer patients most likely to relapse, adding this vaccine erased nearly half the recurrence risk — data that lifted the stock 5.1% on the day.
This reflects a broadening valuation story: the market is no longer pricing Moderna on the flu-vaccine line alone — the cancer vaccine is emerging as a second pillar of support.
What is the next hard catalyst?
The VRBPAC is expected to vote later this week on mFlusiva's benefit-risk profile for adults aged 50 and above.
This means → the vote is the first binary checkpoint for whether the current rally holds — approval opens the path to a formal FDA green light; rejection could give back the recent gains.
Moderna is up 81.8% year-to-date, trading around $56.12 and within striking distance of its 52-week high of $57.80; the closer the stock sits to that ceiling, the more sensitive it becomes to the vote outcome.
Content is for reference only, not financial advice.